James Kevill Malone MD (He/Him)

Endocrinology•Milpitas, CA

Diabetes

Chief Medical Officer

Join to View Full Profile

1820 McCarthy BlvdMilpitas, CA 95035
Phone+1 408-716-5600

Summary

CMO at Bigfoot Biomedical since 2020.

Education & Training

Joslin Diabetes CenterFellowship, Fellowship, Diabetes, 1984 - 1985
The Methodist Hospitals - NorthlakeResidency, Internal Medicine, 1981 - 1984
Indiana University School of MedicineClass of 1981, MD
Butler UniversityBA, Chemistry, Sigma Xi Society, 1974 - 1977

Certifications & Licensure

IN State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine

Clinical Trials

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin Start of enrollment: 2004 May 01
Completed
Phase 3
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents Start of enrollment: 2004 Feb 01
Completed
Phase 2
Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy Start of enrollment: 2004 Sep 01
Completed
Phase 3
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Start of enrollment: 2005 Oct 01
Completed
Phase 3
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Start of enrollment: 2005 Oct 01
Completed
Phase 2
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females Start of enrollment: 2005 Nov 01
Completed
Phase 1
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin Start of enrollment: 2006 Jan 01
Completed
Phase 3
Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Start of enrollment: 2006 Sep 01
Completed
Phase 3
Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes Start of enrollment: 2006 Sep 01
Completed
Phase 3
Effect on Weight Loss of Exenatide Versus Placebo Start of enrollment: 2006 Sep 01
Completed
Phase 3
Safety and Efficacy of Exenatide as Monotherapy Start of enrollment: 2006 Sep 01
Completed
Phase 3
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes Start of enrollment: 2006 Sep 01
Completed
Phase 2
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients Start of enrollment: 2007 Jun 01
Completed
Phase 2
A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes Start of enrollment: 2005 Jan 01
Completed
Phase 1
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy Start of enrollment: 2008 Jan 01
Completed
Join now to see all

Publications & Presentations

PubMed

6 citations
First Real-World Experience With Bigfoot Unity: A 6-Month Retrospective Analysis.
Bantwal S Baliga, John B Tillman, Byron Olson, Sarah Vaughan, F Naureen Sheikh
Clinical Diabetes. 2023-01-01
23 citations
Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
George Grunberger, Anuj Bhargava, Trang T. Ly, Howard Zisser, Liza L. Ilag
Diabetes, Obesity & Metabolism. 2020-03-01
17 citations
Concentrated insulins: History and critical reappraisal.
Lutz Heinemann, John Michael Beals, James Malone, James H. Anderson, Jennie G. Jacobson
Journal of Diabetes. 2019-04-01

James Kevill Malone MD (He/Him)

Dr. Malone is on Doximity

Summary

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.